Trial Profile

A Phase 2/3 Study of AMG531 in Patients With Aplastic Anemia PreviouslyUntreated With Immunosuppressive Therapy

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 13 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Romiplostim (Primary) ; Antithymocyte globulin; Ciclosporin
Indications Aplastic anaemia
Focus Therapeutic Use
Sponsors Kyowa Kirin

Most Recent Events

17 Jun 2022 Results assessing the efficacy and safety of romiplostim combined with rabbit ATG plus CsA in patients with AA requiring transfusions who had not been exposed to IST, presented at the 27th Congress of the European Haematology Association.
25 May 2022 Status changed from active, no longer recruiting to completed.
31 Jul 2020 Planned primary completion date changed from 1 Jul 2020 to 1 Nov 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com